• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Susan Urba Discusses Cost Concerns for Treatment of Chemotherapy-Induced Nausea

Article

In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.

In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.

Related Videos
Interview with Miriam Freimer, MD, The Ohio State University Wexner Medical Center
Merrill H. Stewart, MD
Dr Carrie Kitko
Jeffrey Fitzgerald, JD
Dr Carrie Kitko
Related Content
Graphic of a person cutting a health care price tag in half | Image credit: retrostar - stock.adobe.com

The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access

July 11th 2025
Article

During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.

Read More

Managed Care Cast

Managed Care Cast News Roundup: July 8, 2025

July 8th 2025
Podcast

Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.

Listen

Medicaid | Image credit: Andrii - stock.adobe.com

Experts Highlight Consequences of Medicaid Rollbacks Due to Budget Bill

July 10th 2025
Article

A webinar held by KFF on July 9 emphasized the immediate effects of the new budget bill, highlighting the impacts on Medicaid and health spending in the next decade.

Read More

Managed Care Cast

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

July 1st 2025
Podcast

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

Listen

A cornerstone of the proposed guidance is the emphasis on robust clinical trial design and appropriate patient selection. | Image Credit: wladimir1804 - stock.adobe.com

FDA Releases Draft Guidance for MDS Drug Development

July 10th 2025
Article

The FDA's new guidance shapes drug development for myelodysplastic syndromes (MDS), emphasizing trial design, patient selection, and safety reporting for better treatment outcomes.

Read More

Image credit: Canva Illustration | Mary Caffrey

Using AI for the Medical Note: Game Changer or a Bridge Too Far?

July 9th 2025
Article

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.